ASX ANNOUNCEMENT

New clinical advisory boards

Sydney, 9 December 2021. Actinogen Medical ASX: ACW ("ACW" or "the Company") is pleased to announce the establishment of two new Xanamem® clinical advisory boards for its programs in *Fragile X Syndrome* and *Depression*, and initial expert appointments to those boards.

The Company is delighted to appoint four renowned global thought leaders in clinical trials for Fragile X Syndrome, Depression and assessment of Cognition to add to the preeminent expertise at its disposal on its current Alzheimer's Disease Clinical Advisory Board, comprising distinguished professors Colin Masters AO, Jeffrey Cummings and Craig Ritchie.

The new advisory boards and their inaugural expert appointees are:

Fragile X Syndrome Clinical Advisory Board

- Dr Elizabeth Berry-Kravis, MD, PhD based in the USA
- Dr Pam Ventola, PhD based in the USA

Depression and Cognition Clinical Advisory Board

- Professor John Harrison, PhD, based in the UK
- Dr Dana C. Hilt, MD based in the USA

Dr Steven Gourlay, Actinogen CEO and MD, commented:

"We are honoured to welcome four esteemed global thought leaders to our advisory boards for Fragile X Syndrome, Depression and, more broadly, Cognition and its assessment.

"Actinogen now has additional outstanding world-class expertise at *its disposal to advise on our clinical development strategy across all three of our major clinical trial programs assessing the effectiveness of our lead compound Xanamem in the treatment of Alzheimer's Disease, Fragile X Syndrome and Depression.*

"I look forward to working closely with such renowned experts to help make a material difference to the quality of life for people and their families living with these serious neurological conditions."

Details of the new clinal advisory boards and their expert appointees are:

Fragile X Syndrome Clinical Advisory Board

Dr Elizabeth Berry-Kravis, MD, PhD established the Fragile X Clinic and Research Program at Rush University Medical Center in Chicago in 1992, through which she provides care to over 700 patients with fragile X syndrome (FXS). Dr Berry-Kravis has done extensive work in FXS and has expanded clinical translational work to other neurodevelopmental disorders and genetic neurodegenerative diseases including autism spectrum disorders. Her laboratory studies cellular roles of fragile X mental retardation protein (FMRP), relationship to phenotypes, and optimization of genetic testing methods.

Dr Berry-Kravis is a Professor of Pediatrics, Neurological Sciences, and Biochemistry at Rush University Medical Center in Chicago. She has studied medical issues, epilepsy and psychopharmacology in FXS, and has been a leader in translational research in FXS including development of outcome measures/biomarkers, natural history studies, newborn screening, and particularly clinical trials of new targeted treatments. Dr Berry-Kravis has over 250 publications on genetic neurological diseases and is on several Advisory/Review Boards including those for the FRAXA Research Foundation and the National Fragile X Foundation (USA).

Dr Berry-Kravis attended the University of Notre Dame for undergraduate studies and the University of Chicago for her MD/PhD and training in Paediatric Neurology. Dr Berry-Kravis has received numerous awards and recognition for her work including the FRAXA Champion Award, the American Academy of Neurology Sidney Carter Award in Child Neurology, the FRAXA Ingenuity Award, and the Child Neurology Society Denckla Award for her work in treatment translation for FXS and genetic cognitive disorders.

Dr Pam Ventola, PhD has conducted evaluations of children and adults with developmental disabilities for two decades and has supported numerous international trials in developmental disabilities that involve developmental, cognitive, motor, and behavioural assessments.

Dr Ventola is an Associate Professor at the Yale Child Study Center and leads Cogstate's Rare Disease and Paediatric Center of Excellence and has worked in the field of developmental disabilities for over twenty years. She has more than 100 related publications, conference presentations, invited addresses, and book chapters, and has published a book on diagnostic assessment. Dr Ventola also serves on advisory panels and academic review committees and has extensive clinical and research experience with paediatric neuropsychological and developmental assessments as well as the Cogstate computerized cognitive testing battery.

Dr. Ventola attended Hamilton College for her undergraduate degree and the University of Connecticut, under the mentorship of Dr. Deborah Fein, for her doctoral degree. She completed her clinical training and post-doctoral fellowship at the Yale Child Study Center.

Depression and Cognition Clinical Advisory Board

Professor John Harrison is an expert psychologist with a special interest in cognition whose principal professional interest is in helping people understand, maintain, and enhance their cognitive skills.

Professor Harrison is Principal Consultant at Metis Cognition, a psychology practice established to advise with the selection and successful integration of cognitive testing into therapeutic development programs. He is also an Associate Professor with the AUmc Alzheimer Center and Visiting Professor at King's College London. Professor Harrison holds Chartered Psychologist status and has authored/co-authored more than 80 books and scientific articles, including a popular neuroscience book 'Synaesthesia: The Strangest Thing'.

After acquiring a first-class honours degree in psychology Professor Harrison earned his first PhD from the University of London science faculty. He has held research posts at various UK institutions, including Charing Cross & Westminster Medical School, Imperial College London and the University of Cambridge.

Dr Dana C. Hilt MD has more than 25 years of drug development experience, primarily of Central Nervous System (CNS) drugs. Dr Hilt has deep experience in Phases 1 to 4 development of drugs for conditions including Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, Schizophrenia, and other non-CNS conditions.

Dr Hilt is currently the Chief Medical Officer at Frequency Therapeutics and has held senior development and management positions as Chief Medical Officer at various pharmaceutical companies, including Guilford Pharmaceuticals, Ascend Pharmaceuticals, and Critical Therapeutics, Prior to that, Dr Hilt worked with Amgen, establishing a Clinical Neuroscience Group that focused on the potential therapeutic applications of neurotrophic factors in degenerative neurologic diseases such as Parkinson's disease.

Dr Hilt gained his medical degree from Tufts University School of Medicine in Boston and trained in Internal Medicine at Harvard Medical School and Neurology at the Johns Hopkins Hospital. He has held academic Neurology positions at the University of Maryland and University of Southern California where he conducted molecular biological research, taught clinical Neurology and basic neurobiology, and cared for patients with Neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and ALS.

ENDS

	Investors	**Media**
Dr. Steven Gourlay CEO & Managing Director P: +61 2 8964 7401 E. steven.gourlay@actinogen.com.au	**Michael Roberts** Investor Relations P: +61 2 8964 7401 E. michael.roberts@actinogen.com.au	**Randal Killip** Profile for Media M: +61 425 714 159 E. randal@profileformedia.com.au

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.

Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influence our personality.

We are currently developing our lead compound, Xanamem®, as a promising new therapy for Alzheimer's Disease, Fragile X Syndrome, Depression and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem®

Xanamem's novel mechanism of action works by blocking the production of intracellular cortisol through the inhibition of the 11β-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule.

Chronically elevated cortisol is associated with cognitive decline in Alzheimer's Disease, potentially linked to cognitive impairment and anxiety in Fragile X Syndrome, and cognitive impairment in Depression and other diseases.

The Company has studied 11β-HSD1 inhibition by Xanamem in more than 250 volunteers and patients, so far finding a statistically significant improvement in cognition over placebo in healthy, older volunteers. A series of Phase 2 studies in multiple diseases is being conducted to further confirm and characterise Xanamem's therapeutic potential.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies, and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP.